Figure 3
Anti-Gr1 antibody depletes neutrophils in the cornea but does not have an appreciable impact on corneal neovascularization. (a) Representative flow cytometry plots indicating myeloid cells, CD3+NK1.1− T cells, and NK cells in the blood at day 14 post infection (pi) comparing isotype control antibody-treated mice to Gr1-depleting antibody-treated animals. Myeloid cells were gated on CD45+CD3−CD11b+ population. (b) Quantification of leukocytes in the blood at day 14 pi following antibody administration. (c) Representative flow cytometric plots indicating myeloid cells, NK cells, and T cells at day 14 pi comparing isotype control antibody-treated mice to anti-Gr1 antibody-treated mice. (d) Quantification of infiltrating leukocytes in the cornea at day 14 pi post antibody treatment. (e) Representative images of Z-stacked corneas at day 14 pi comparing isotype control antibody-treated mice to anti-Gr1 antibody-treated animals. (f,g) Metamorph quantification of corneal area containing lymphatic (green) and blood (red) vessels per × 100 field of view. Bar=200 μm. Data represent summary of mean±s.e.m. of two independent experiments with n=5–8 mice (a,b), n=5–6 mice (c–g). *P<0.05, **P<0.01, ***P<0.001, as determined by Student’s t-test.
